Cerevel Therapeutics: Time For A Risk Arbitrage Play?

koto_feja Introduction Cerevel Therapeutics (Nasdaq: NASDAQ:CERE) was created as a spinout for Pfizer's (NYSE: PFE) central nervous system pipeline assets. The birthing process involved Perceptive Advisors using its ARYA II SPAC to effectively buy the assets with Bain Capital for $439.5M on 07/29/20, and then launch and rename the company to Cerevel. CERE focused diligently on its lead assets, taking them from the early clinic into placebo controlled studies, and even got one asset into phase 3 studies. The ...